Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fully Validated, Multi-Kilogram cGMP Synthesis of MDMA.

Jay B Nair1, Linda Hakes2, Berra Yazar-Klosinski3

  • 1MAPS Public Benefit Corporation (MAPS PBC), 3141 Stevens Creek Blvd #40547, San Jose, California 95117, United States.

ACS Omega
|January 17, 2022
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysis.

CPT: pharmacometrics & systems pharmacology·2024
Same author

Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.

Nature medicine·2024
Same author

Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.

Psychopharmacology·2024
Same author

Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.

Psychopharmacology·2024
Same author

MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.

Nature medicine·2023
Same author

MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.

Focus (American Psychiatric Publishing)·2023
Same journal

NMR Spectroscopy: Molecular Insights into Cell Wall Collapse and Oxidative Stress of <i>Escherichia coli</i> Induced by Imidazole-Activated Eutectic Solvents.

ACS omega·2026
Same journal

Enhanced Arsenite Remediation in Synthetic FeS<sub>2</sub>/Fe(II)-Containing Arsenic Wastewater via Epigallocatechin Gallate-Initiated Persulfate Activation.

ACS omega·2026
Same journal

Defect and Particle-Size Engineering as Mechanistic Drivers for Dye Uptake in a Zirconium Metal-Organic Framework.

ACS omega·2026
Same journal

Biogeochemical Assessment of Short-Term Hydrogen Storage in Methane Reservoirs with Field Sample Characterization and Reactor Experiments.

ACS omega·2026
Same journal

Combined Effects of Halloysite Nanotubes, Nucleating Agent, and Thermal Annealing on the Printability and Mechanical Performances of 3D-Printable Polypropylene Random Copolymer-Based Composites.

ACS omega·2026
Same journal

Effect of MoS<sub>2</sub> Interfacial Engineering across MAPbI<sub>3</sub>, FAPbI<sub>3</sub>, and CsPbI<sub>3</sub> Perovskite Solar Cells.

ACS omega·2026
See all related articles

Researchers developed a validated Good Manufacturing Practice (cGMP) synthesis for 3,4-Methylenedioxymethamphetamine (MDMA). This scalable process ensures high purity MDMA for clinical trials and potential therapeutic applications.

Area of Science:

  • Pharmaceutical Chemistry
  • Drug Manufacturing
  • Clinical Research

Background:

  • 3,4-Methylenedioxymethamphetamine (MDMA) is gaining traction in clinical research.
  • A standardized, Good Manufacturing Practice (cGMP)-compliant synthesis for MDMA has been lacking.
  • This gap hinders large-scale clinical trials and potential therapeutic development.

Purpose of the Study:

  • To report the first fully validated cGMP synthesis of MDMA.
  • To establish a scalable and reproducible manufacturing process for clinical-grade MDMA.
  • To ensure a reliable supply of high-purity MDMA for ongoing and future research.

Main Methods:

  • A four-step synthesis process was developed, starting from a noncontrolled material.
  • The synthesis was validated under cGMP conditions.

Related Experiment Videos

  • High-performance liquid chromatography (HPLC) was used to assess chemical purity.

    • Main Results:

    • The synthesis successfully produced up to 5 kg of MDMA (approximately 30,000 patient doses).
    • Overall yield ranged from 41-53% over the four steps.
    • Chemical purity consistently exceeded 99.9% by HPLC peak area across validation trials.

    Conclusions:

    • The described cGMP synthesis provides a validated method for producing high-purity MDMA.
    • This advancement will support ongoing clinical trials investigating MDMA.
    • Availability of cGMP MDMA is crucial for future therapeutic use, pending regulatory approval.